Lupin bags approval for Fluoxetine Tablets USP 10 mg, 20 mg

Lupin has received approval for its Fluoxetine Tablets USP after receiving approval from USFDA.

Fluoxetine Tablets USP, 10 mg and 20 mg, will be marketed by Lupin after the company announced on getting the approval from the United States Food and Drug Administration (USFDA)

The company’s Fluoxetine Tablets USP, 10 mg and 20 mg, is the generic version of Eli Lilly’s Prozac Tablets, 10 mg and 20 mg. Fluoxetine Tablets, 10 mg and 20 mg. It had annual sales of approximately US$68.2 million in the US according to IQVIA MAT December 2018.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

On Tuesday, the shares of Lupin opened at Rs. 831 against Monday’s close of Rs. 830.2. The shares closed at Rs. 833.9, up by 0.45 per cent. It reached an intraday high of Rs. 843.95 and an intraday low of Rs. 827.10 per share on the BSE. The 52-week high stood at Rs. 986 and 52-week low was at Rs. 720.4 per share on the BSE.